person · Reporting owner
Start Valerie Denise Harding
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Erasca, Inc.ERAS · Entity 3796 | Director | June 26, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Erasca, Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01 · Expires 2036-06-26 | Direct | 29,888 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 29,888 · Balance 29,888 F1: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ignyta, Inc.
Report date February 08, 2018 · Filed February 12, 2018
Section 16 reporting ended · disclosed 2018-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 1
1 source rowRow 1 · 2018-02-08 · Disposition to issuer · Disposed 29,188 · Balance 0 F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.47 · Expires 2025-09-01 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-08 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2027-01-04 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-08 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").
F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 29, 2026 23:07 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock option (right to buy) · Derivative | 29,888 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001193125-26-288910 · ownership.xml · derivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,888 Underlying: Common Stock · 29,888 shares Expires 2036-06-26 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 14:00 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 24,306 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001193125-26-001608 · ownership.xml · derivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,306 Underlying: Common Stock · 24,306 shares Expires 2036-01-01 F1 · security: At the election of the filing person the option grant was issued in lieu of the cash compensation payable to such person in 2026 in connection with each position on the issuer's board of directors and its committees for which such person is anticipated to serve in 2026. F2 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12 increments beginning one month from the date of grant, subject to such person continuing to serve on the issuer's board of directors through the applicable vesting date. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:26 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock option (right to buy) · Derivative | 120,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000950170-25-090422 · ownership.xml · derivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 24, 2026, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 01:19 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 29,402 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0000950170-25-000635 · ownership.xml · derivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,402 Underlying: Common Stock · 29,402 shares Expires 2035-01-01 F1 · security: At the election of the filing person the option grant was issued in lieu of the cash compensation payable to such person in 2025 in connection with each position on the issuer's board of directors and its committees for which such person is anticipated to serve in 2025. F2 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12 increments beginning one month from the date of grant, subject to such person continuing to serve on the issuer's board of directors through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 12:52 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-24-005928 · doc4.xml · derivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 20, 2025, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 14:00 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 39,590 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001209191-24-000269 · doc4.xml · derivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,590 Underlying: Common Stock · 39,590 shares Expires 2034-01-01 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments beginning one month from the date of grant, subject to such person's continuing in service on the board through the applicable vesting date. F2 · derivative.underlying_shares: At the election of the filing person, the option grant was issued in lieu of direct cash compensation payable to such person in 2024 in connection with each position on the board and its committees for which such person is anticipated to serve in 2024. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 14:10 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 10,000 | $1.85 | $18,480.00 |
DisclosureSEC source: 0001209191-23-057833 · doc4.xml · nonDerivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Start 2006 Trust Disclosed balance after: 20,000 F1 · ownership.nature: The securities reported herein as being purchased were purchased by the Start 2006 Trust. Such securities may be deemed to be beneficially owned by the Reporting Person, who with her spouse are the co-trustees of the Start 2006 Trust. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 13:11 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-23-039585 · doc4.xml · derivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2024, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 02:28 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 10,000 | $4.64 | $46,400.00 |
DisclosureSEC source: 0001209191-22-062537 · doc4.xml · nonDerivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Start 2006 Trust Disclosed balance after: 10,000 F1 · ownership.nature: The securities reported herein as being purchased were purchased by the Start 2006 Trust. Such securities may be deemed to be beneficially owned by the Reporting Person, who with her spouse are the co-trustees of the Start 2006 Trust. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 13:17 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-22-039104 · doc4.xml · derivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:49 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 2,000 | $16.00 | $32,000.00 |
DisclosureSEC source: 0000899243-21-029068 · doc4.xml · nonDerivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 15:35 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-18-009152 · doc4.xml · derivative · entry 3 Start Valerie Denise Harding · CIK 0001652037 · SVP, Chemistry, Mfg & Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2027-01-04 F2 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 15:35 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0001209191-18-009152 · doc4.xml · derivative · entry 2 Start Valerie Denise Harding · CIK 0001652037 · SVP, Chemistry, Mfg & Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2025-09-01 F2 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 15:35 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerCommon Stock | 29,188 | $27.00 | $788,076.00 |
DisclosureSEC source: 0001209191-18-009152 · doc4.xml · nonDerivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · SVP, Chemistry, Mfg & Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 21:37 UTC | Ignyta, Inc. RXDX · Entity 169521 | Tax withholdingCommon Stock | 2,066 | $26.70 | $55,162.20 |
DisclosureSEC source: 0000899243-17-029705 · doc4.xml · nonDerivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · SVP, Chemistry, Mfg & Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,188 Read SEC document |
| December 22, 2017 Filed Dec 22, 2017 21:50 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantCommon Stock | 23,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067165 · doc4.xml · nonDerivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · SVP, Chemistry, Mfg & Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,254 F1 · shares: Represents the grant of restricted stock units to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest as to 25% of the shares underlying each award on each anniversary of the Grant Date, subject to the Reporting Person's continues service with the Company through the vesting date. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 18:56 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-17-002773 · doc4.xml · derivative · entry 1 Start Valerie Denise Harding · CIK 0001652037 · SVP, Chemistry, Mfg & Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: The option is exercisable as it vests. 25% of the shares subject to the option vest on January 5, 2018, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.